In what may be one of the most important HIV research breakthroughs in years, scientists have discovered a strikingly ...

CFO Robert E. Hoffman to deliver company presentation on October 21, 2025 VANCOUVER, Washington, Oct. 09, 2025 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a ...

Researchers have discovered the antibody 04_A06, which neutralizes the human immunodeficiency virus (HIV) in almost all ...

The FDA has granted Fast Track designation to Bristol Myers Squibb’s anti-MTBR-tau antibody (BMS-986446) for the treatment of early Alzheimer disease.

Patients with severe asthma receiving mepolizumab experience reductions in healthcare resource use and improvements in work ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced it has initiated three Phase 2b trials ...

Leap Therapeutics ( ($LPTX) ) has shared an update. On October 6, 2025, Leap Therapeutics entered into a Securities Purchase Agreement for a ...

Merck, known as MSD outside of the United States and Canada, announced it has initiated three phase 2b trials evaluating the safety and efficacy of tulisokibart (MK-7240), an investigational humanized ...

Leqembi Iqlik, a subcutaneous formation of lecanemab, is now available as a maintenance dosing regimen for the treatment of early Alzheimer disease.